Information Provided By:
Fly News Breaks for July 29, 2015
EW
Jul 29, 2015 | 07:46 EDT
Canaccord raised its price target on Edwards Lifesciences to $178 from $160 following positive Q2 results. The stock remains Canaccord's favorite med-tech large cap name, citing the market expansion of TAVI and its belief the penetration is in its early stages. The firm also cited its operating leverage, its TMVR program and sizable war-chest to acquire other promising technologies. Canaccord reiterated its Buy rating on Edwards Lifesciences shares.